- RecruitingPHASE2, PHASE3
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
This study, called FORMaT, is looking for the best ways to treat a serious lung infection called Mycobacterium abscessus (MABS-PD). It tests different medicines to find the most effective and safest treatments, aiming to improve how people with this condition live.
For: Pulmonary Disease Due to Mycobacteria (Diagnosis)Australia · Denmark · Israel - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-XNW4107 in Comparison with Imipenem/Cilastatin/Relebactam in Adults with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
This study looks at new treatments for severe lung infections caught in hospital, like pneumonia. It compares a new medicine (XNW4107) with an existing one (Recarbrio) to see which is safer and more effective at helping patients recover and survive.
For: Hospital-acquired bacterial pneumonia (HABP) · including ventilated HABP (vHABP) and ventilator-associated bacterial pneumonia (VABP) caused by Gram-negative bacteriaFrance · Spain - Ongoing, recruitingTherapeutic use (Phase IV)
SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non-inferiority trial
This study looks at treating a fever and low white blood cell count in cancer patients called febrile neutropenia. It compares giving antibiotics for a short time versus longer, checking if the shorter treatment is just as safe and effective.
For: Febrile neutropeniaBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem Resistant Enterobacterales (OP0595-6)
This study looks at new medicines for serious bacterial infections like complicated urine infections, pneumonia, and tummy infections. Researchers want to see if these new treatments work better and are safer than current standard care, especially for infections resistant to common antibiotics.
For: Complicated urinary tract infection (cUTI) · acute uncomplicated pyelonephritis (AP) · hospital acquired bacterial pneumonia (HABP)France · Czechia · Greece - AuthorisedTherapeutic use (Phase IV)
TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial
This study is looking at the best length of antibiotic treatment for liver abscesses, comparing 3 weeks to 6 weeks. It wants to see if shorter treatment is just as effective and safe as longer treatment for patients after their abscess has been drained.
For: Pyogenic liver abscessFrance - AuthorisedTherapeutic use (Phase IV)
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
This study looks at how well antibiotics work in very sick patients. Researchers want to make sure these important medicines reach the right levels in the body to fight serious infections effectively and safely. It's about getting the dose just right.
For: Serious infections in critically ill patients treated with antibioticsFrance